اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,219
تعداد مقالات35,690
تعداد مشاهده مقاله53,569,436
تعداد دریافت فایل اصل مقاله92,849,030
Arzani, Fatemeh, Mostofi Fakhrani, Zahra, Omranzadeh, Alireza, Safarian, Samin, Soltani, Danial, Soroushianfar, Mahdi. (1404). Harnessing Listeria monocytogenes: A Promising Approach to Cancer Treatment. سامانه مدیریت نشریات علمی, 80(2), 275-284. doi: 10.32592/ARI.2025.80.2.275
Fatemeh Arzani; Zahra Mostofi Fakhrani; Alireza Omranzadeh; Samin Safarian; Danial Soltani; Mahdi Soroushianfar. "Harnessing Listeria monocytogenes: A Promising Approach to Cancer Treatment". سامانه مدیریت نشریات علمی, 80, 2, 1404, 275-284. doi: 10.32592/ARI.2025.80.2.275
Arzani, Fatemeh, Mostofi Fakhrani, Zahra, Omranzadeh, Alireza, Safarian, Samin, Soltani, Danial, Soroushianfar, Mahdi. (1404). 'Harnessing Listeria monocytogenes: A Promising Approach to Cancer Treatment', سامانه مدیریت نشریات علمی, 80(2), pp. 275-284. doi: 10.32592/ARI.2025.80.2.275
Arzani, Fatemeh, Mostofi Fakhrani, Zahra, Omranzadeh, Alireza, Safarian, Samin, Soltani, Danial, Soroushianfar, Mahdi. Harnessing Listeria monocytogenes: A Promising Approach to Cancer Treatment. سامانه مدیریت نشریات علمی, 1404; 80(2): 275-284. doi: 10.32592/ARI.2025.80.2.275

Harnessing Listeria monocytogenes: A Promising Approach to Cancer Treatment

Archives of Razi Institute
مقاله 2، دوره 80، شماره 2، خرداد و تیر 2025، صفحه 275-284    اصل مقاله (597.18 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.32592/ARI.2025.80.2.275
نویسندگان
Fatemeh Arzani1؛ Zahra Mostofi Fakhrani2؛ Alireza Omranzadeh* 3؛ Samin Safarian4؛ Danial Soltani4؛ Mahdi Soroushianfar5
1Graduate student of the Plant Biology Department, University of Nazlu Urmia, Iran
2Islamic Azad University of Shoushtar, Khuzestan, Iran
3Medical doctor, Mashhad University of Medical Sciences, Mashhad, Iran
4Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
چکیده
Increasing mortality and morbidity rates have drawn global attention to cancer, prompting the exploration of new treatment options. The use of immunotherapy for recurrent or metastatic cancer has emerged as a promising option over the years despite its limitations as compared to traditional treatment options. Among the various immunotherapeutic approaches, bacterial-based vectors like Listeria monocytogenes (Lm) have garnered attention for their unique characteristics. Utilizing these vectors involves leveraging their ability to invade Antigen-Presenting Cells (APCs), grow intracellularly within immune cells, and spread intracellularly, enhancing their efficacy in tailoring immune responses. It is important to note that the use of bacterial vectors significantly minimizes the risks associated with off-target effects. The antitumor effects of Lm can be observed through the reduction of immunosuppressive cells in the tumor microenvironment as well as the stimulation of T cells. Various types of tumor cells can be targeted by modified Lm vaccines, according to research. However, it is recognized that Lm vaccines alone may not suffice for comprehensive cancer treatment. Therefore, using Lm vaccines in combination with other therapeutic modalities like radiotherapy, reactivated adoptive cell therapy, and immune checkpoint inhibitors could result in superior results. As a result of these developments, the current review aims to elaborate on recent developments in the understanding of how Lm vaccines perform their antitumor properties. This review aims to provide insights into optimizing the therapeutic potential of Lm vaccines by comprehensively examining their interplay with the immune system. In order to harness the full therapeutic potential of Lm vaccines for fighting cancer, researchers and clinicians need to gain a deeper understanding of these mechanisms.
کلیدواژه‌ها
Listeria monocytogenes؛ Cancer؛ Cancer vaccine؛ Immunotherapy؛ Tumor
عنوان مقاله [English]
لیستریا مونوسیتوژنز به عنوان یک عامل پاتوژن دامپزشکی برای مبارزه با سرطان‌ها
چکیده [English]
چشم‌انداز جهانی به سرطان به دلیل نرخ مرگ و میر چشمگیر آن تشدید شده است که منجر به بررسی روش‌های درمانی نوآورانه شده است. ایمونوتراپی به عنوان یک گزینه امیدبخش برای بیماران مبتلا به سرطان متاستاتیک به وجود آمده است که محدودیت‌های درمان‌های سنتی را برطرف می‌کند. از میان رویکردهای ایمونوتراپی مختلف، درمان بر پایه باکتری مانند لیستریا مونوسیتوژنز (Lm) به دلیل ویژگی‌های منحصر به فرد خود، توجه بسیاری را به خود جلب کرده‌اند. استفاده از این باکتری شامل بهره‌گیری از توانایی آن‌ها برای تهاجم به سلول‌های آنتی‌ژن‌پرداز (APC)، رشد در داخل سلول‌های ایمنی و گسترش درون‌سلولی است، که بهبود کارآیی آن‌ها در سازماندهی پاسخ‌های ایمنی منجر می‌شود. از اهمیت ویژه استفاده از باکتریایی میتوان به کم کردن خطر اثرات جانبی شیمی درمانی یا پرتودرمانی و جراحی اشاره کرد. لیستریا مونوسیتوژنز اثرات ضد توموری قوی را با کاهش سلول‌های ایمنی‌ساز، افزایش فعالیت سلول‌های T در محیط تومور نشان می‌دهد. تحقیقات نشان می‌دهد که واکسن‌های Lm تغییر یافته می‌توانند پاسخ‌های ایمنی متنوعی را به سلول‌های مختلف توموری القا کنند. با این حال، واکسن‌های Lm به تنهایی ممکن است برای درمان جامع سرطان کافی نباشند. بنابراین، ترکیب واکسن‌های Lm با سایر روش‌ها مانند درمان سلول‌های بیماری‌ای بازفعال‌شده، رادیوتراپی و مهارکننده‌های چک‌پوینت ایمنی امیدواری به بهبود نتایج درمانی دارد. با توجه به این پیشرفت‌ها، بررسی حاضر به بررسی پیشرفت‌های اخیر در درک مکانیسم‌های مولکولی در پایگاه ضد توموری واکسن‌های Lm می‌پردازد. با بررسی جامع تعامل پیچیده بین واکسن‌های Lm و سیستم ایمنی، این بررسی به هدف ارائه بینش‌ها در بهینه‌سازی قدرت درمانی آن‌ها در زمینه درمان سرطان می‌پردازد. از طریق درک عمیق‌تر این مکانیسم‌ها، پژوهشگران و پزشکان می‌توانند استراتژی‌های نوآورانه‌ای را برای بهره‌گیری از مزایای کامل درمانی واکسن‌های Lm در مبارزه با سرطان ارائه دهند.
کلیدواژه‌ها [English]
لیستریا مونوسیتوژنز, سرطان، واکسن سرطان، ایمونوتراپی، تومور
سایر فایل های مرتبط با مقاله
مراجع
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
  2. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2022.
  3. Higano CS. Sipuleucel-T: autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. Drug Management of Prostate Cancer. 2010:321-8.
  4. Sadr S, Yousefsani Z, Simab PA, Alizadeh AJR, Lotfalizadeh N, Borji H. Trichinella spiralis as a potential antitumor agent: An update. World's Veterinary Journal. 2023;13(1):65-74.
  5. Lotfalizadeh N, Sadr S, Morovati S, Lotfalizadeh M, Hajjafari A, Borji H. A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii. Cancer Reports. 2024;7(2):e1963.
  6. Naseri A, Matoofi A, Mansouri Ramezani M, Kalantari L, Taherzadeh Amlashi T, Roudaki S, et al. Comprehensive analysis of Papillomavirus (PV) and its implications in cancer: Bridging the gap between human and veterinary medicine. Archives of Razi Institute. 2024.
  7. Ameli N, Babazadeh D, Seifdavati B, Gevarigz Sangar S, Babayi MM, Soltani D, et al. Utilizing Aspergillus Fungi, a Significant Veterinary Pathogen, in Lung Cancer Treatment: A Novel Approach. Archives of Razi Institute. 2024.
  8. Rajaei N, Faraji N, Khabaz PB, Yousefi M, Khavidaki NL, Omranzadeh A. The Role of Newcastle Disease Virus in Cancer Therapy: A Systematic Review. Journal of World's Poultry Research. 2023;13(4):373-85.
  9. Sadr S, Borji H. Echinococcus granulosus as a promising therapeutic agent against triplenegative breast cancer. Current Cancer Therapy Reviews. 2023;19(4):292-7.
  10. Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer. 2018;18(12):727-43.
  11. Flickinger Jr JC, Rodeck U, Snook AE. Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress. Vaccines. 2018;6(3):48.
  12. Yang M, Yang F, Chen W, Liu S, Qiu L, Chen J. Bacteria-mediated cancer therapies: opportunities and challenges. Biomaterials Science. 2021;9(17):5732-44.
  13. Pizarro-Cerdá J, Kühbacher A, Cossart P. Entry of Listeria monocytogenes in mammalian epithelial cells: an updated view. Cold Spring Harbor perspectives in medicine. 2012;2(11):a010009.
  14. Aubry C, Corr SC, Wienerroither S, Goulard C, Jones R, Jamieson AM, et al. Both TLR2 and TRIF contribute to interferon-β production during Listeria infection. PloS one. 2012;7(3):e33299.
  15. Köster S, Van Pee K, Hudel M, Leustik M, Rhinow D, Kühlbrandt W, et al. Crystal structure of listeriolysin O reveals molecular details of oligomerization and pore formation. Nature communications. 2014;5(1):3690.
  16. Tattoli I, Sorbara MT, Yang C, Tooze SA, Philpott DJ, Girardin SE. Listeria phospholipases subvert host autophagic defenses by stalling pre‐autophagosomal structures. The EMBO journal. 2013;32(23):3066-78.
  17. Miles BA, Monk BJ, Safran HP. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecologic oncology research and practice. 2017;4:1-12.
  18. Lambrechts A, Gevaert K, Cossart P, Vandekerckhove J, Van Troys M. Listeria comet tails: the actin-based motility machinery at work. Trends Cell Biol. 2008;18(5):220-7.
  19. Sleator RD, Watson D, Hill C, Gahan CGM. The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology (Reading). 2009;155(Pt 8):2463-75.
  20. Broeker NP. Listeria monocytogenes inlA/inlB as possible drug delivery systems. Wiley Online Library; 2013.
  21. Yang Y, Hou J, Lin Z, Zhuo H, Chen D, Zhang X, et al. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cellular & Molecular Immunology. 2014;11(2):184-96.
  22. Wallecha A, Wood L, Pan Z-K, Maciag PC, Shahabi V, Paterson Y. Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Clinical and Vaccine Immunology. 2013;20(1):77-84.
  23. Campillo-Navarro M, Leyva-Paredes K, Donis-Maturano L, González-Jiménez M, Paredes-Vivas Y, Cerbulo-Vázquez A, et al. Listeria monocytogenes induces mast cell extracellular traps. Immunobiology. 2017;222(2):432-9.
  24. Mirzaei R, Saei A, Torkashvand F, Azarian B, Jalili A, Noorbakhsh F, et al. Identification of proteins derived from Listeria monocytogenes inducing human dendritic cell maturation. Tumor Biology. 2016;37:10893-907.
  25. Wood LM, Guirnalda PD, Seavey MM, Paterson Y. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunologic research. 2008;42:233-45.
  26. Liang ZZ, Sherrid AM, Wallecha A, Kollmann TR. Listeria monocytogenes: a promising vehicle for neonatal vaccination. Human vaccines & immunotherapeutics. 2014;10(4):1036-46.
  27. Vinodhini K, Shanmughapriya S, Das BC, Natarajaseenivasan K. Prevalence and risk factors of HPV infection among women from various provinces of the world. Archives of gynecology and obstetrics. 2012;285:771-7.
  28. Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecologic oncology. 2014;133(3):439-45.
  29. Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes–Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. International Journal of Gynecologic Cancer. 2018;28(4).
  30. Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J. Lm-LLO-based immunotherapies and HPV-associated disease. Journal of oncology. 2012;2012.
  31. Zhao KN, Chen J. Codon usage roles in human papillomavirus. Reviews in medical virology. 2011;21(6):397-411.
  32. Duan F, Chen J, Yao H, Wang Y, Jia Y, Ling Z, et al. Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7. Human Vaccines & Immunotherapeutics. 2021;17(6):1568-77.
  33. Qian Y, Zhang N, Jiang P, Chen S, Chu S, Hamze F, et al. Inhibitory effect of live-attenuated Listeria monocytogenes-based vaccines expressing MIA gene on malignant melanoma. Journal of Huazhong University of Science and Technology [Medical Sciences]. 2012;32:591-7.
  34. Maciag PC, Seavey MM, Pan Z-K, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer research. 2008;68(19):8066-75.
  35. Vitiello M, Evangelista M, Di Lascio N, Kusmic C, Massa A, Orso F, et al. Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene. 2019;38(19):3756-62.
  36. Lim JY, Brockstedt DG, Lord EM, Gerber SA. Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncoimmunology. 2014;3(6):e29028.
  37. Kim S, Castro F, Gonzalez D, Maciag P, Paterson Y, Gravekamp C. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. British journal of cancer. 2008;99(5):741-9.
  38. Singh M, Quispe-Tintaya W, Chandra D, Jahangir A, Venkataswamy M, Ng T, et al. Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy. British journal of cancer. 2014;111(10):1945-54.
  39. Singh M, Ramos I, Asafu‐Adjei D, Quispe‐Tintaya W, Chandra D, Jahangir A, et al. Curcumin improves the therapeutic efficacy of L isteriaat‐M age‐b vaccine in correlation with improved T‐cell responses in blood of a triple‐negative breast cancer model 4T1. Cancer medicine. 2013;2(4):571-82.
  40. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. The Journal of Immunology. 2002;169(12):6842-9.
  41. Clancy E. ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline. Renal & Urology News. 2023:NA-NA.
  42. Stein MN, Fong L, Tutrone R, Mega A, Lam ET, Parsi M, et al. ADXS31142 immunotherapy±pembrolizumab treatment for metastatic castration-resistant prostate cancer: open-label phase I/II KEYNOTE-046 study. The oncologist. 2022;27(6):453-61.
  43. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al. Roles for Nkx3. 1 in prostate development and cancer. Genes & development. 1999;13(8):966-77.
  44. Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, et al. Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clinical Cancer Research. 2019;25(19):5787-98.
  45. Singh R, Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Human vaccines. 2011;7(5):497-505.
  46. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of clinical Oncology. 2015;33(12):1325.
  47. Schuchat A. Infections caused by Listeria monocytogenes. Harrison's Principles of Internal Medicine. 2001.
  48. Oladejo M, Paulishak W, Wood L, editors. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology; 2023: Elsevier.
  49. Cruz MS, Diamond A, Russell A, Jameson JM. Human αβ and γδ T cells in skin immunity and disease. Frontiers in immunology. 2018;9:368640.
  50. Ding Y-D, Shu L-Z, Deng H. Listeria monocytogenes: a promising vector for tumor immunotherapy. Frontiers in Immunology. 2023;14:1278011.
آمار
تعداد مشاهده مقاله: 1,010
تعداد دریافت فایل اصل مقاله: 954


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب